Wells Fargo Initiates Coverage On Denali Therapeutics with Overweight Rating, Announces Price Target of $35
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsInitiationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Wells Fargo analyst Benjamin Burnett initiates coverage on Denali Therapeutics (NASDAQ:DNLI) with a Overweight rating and announces Price Target of $35.
Wells Fargo analyst Benjamin Burnett initiates coverage on Denali Therapeutics (NASDAQ:DNLI) with a Overweight rating and announces Price Target of $35.